Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies  Ensi Voshtina,

Slides:



Advertisements
Similar presentations
Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Advertisements

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.
A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis  Sonali.
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.
The Clinical Impact of Infection with Swine Flu (H1N109) Strain of Influenza Virus in Hematopoietic Stem Cell Transplant Recipients  Biju George, Patricia.
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.
A Prospective Study Comparing the Outcomes and Health-Related Quality of Life in Adult Patients with Myeloid Malignancies Undergoing Allogeneic Transplantation.
Biology of Blood and Marrow Transplantation
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis 
Betty T. Tran, Abigail Halperin, Jason W. Chien 
Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation  David A. Jacobsohn, Brad Hewlett, Elaine Morgan,
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia  Hien K. Duong, MD, Mojtaba Akhtari, MD, Kwang Woo Ahn, PhD, Zhen-Huan.
Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Extranodal Natural Killer (Nk)/T-Cell Lymphoma, Nasal Type (ENKL): A CIBMTR Analysis  Abraham.
The Clinical Impact of Infection with Swine Flu (H1N109) Strain of Influenza Virus in Hematopoietic Stem Cell Transplant Recipients  Biju George, Patricia.
Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation  Zachariah DeFilipp, Elizabeth.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Ayman.
Biology of Blood and Marrow Transplantation
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups  H. Joachim Deeg, Christopher.
Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic.
Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation  Navneet.
B Cells and Transplantation: An Educational Resource
Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse.
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients  James L. Gajewski, Mark.
Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation?  Melhem.
Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International.
Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation  Merav Bar, Weigang Tong, Megan Othus,
Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis  Jason.
Stratification of Allogeneic Hematopoietic Cell Transplant Patients by Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score 
The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group  Amber B. Clemmons,
Biology of Blood and Marrow Transplantation
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
Importance of Site Preparation in Reducing the Risk of Bacterial Contamination during Bone Marrow Harvest  Maheen Z. Abidi, Cassandra Stoll, Anita D'Souza,
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation 
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience 
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Biology of Blood and Marrow Transplantation
Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives  Minakshi Raj, Sung Won Choi,
Blood and Marrow Transplant Handbook
A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation  Philippe Armand, Haesook.
Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.
Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse 
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation  Abraham S. Kanate, Parameswaran.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma  Luciano J. Costa, Jia-Xing Huang, Parameswaran.
Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic.
Presentation transcript:

Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies  Ensi Voshtina, Aniko Szabo, Mehdi Hamadani, Timothy S. Fenske, Anita D'Souza, Saurabh Chhabra, Wael Saber, William R. Drobyski, Parameswaran Hari, Nirav N. Shah  Biology of Blood and Marrow Transplantation  Volume 25, Issue 1, Pages e33-e38 (January 2019) DOI: 10.1016/j.bbmt.2018.08.031 Copyright © 2018 Terms and Conditions

Figure 1 OS (A) and PFS (B) in the BMI <30 and BMI ≥30 groups. Biology of Blood and Marrow Transplantation 2019 25, e33-e38DOI: (10.1016/j.bbmt.2018.08.031) Copyright © 2018 Terms and Conditions

Figure 2 OS (A) and PFS (B) in the BMI <30 and BMI ≥35 groups. Biology of Blood and Marrow Transplantation 2019 25, e33-e38DOI: (10.1016/j.bbmt.2018.08.031) Copyright © 2018 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.